pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Optune Lua, the most common co-covered peer. We currently track 1 Biotech story that mention NovoCure Limited, all published on February 26, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about NovoCure Limited
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Optune Lua, the most common co-covered peer. We currently track 1 Biotech story that mention NovoCure Limited, all published on February 26, 2026. Each carries 7 original sources on average.
Stories tracked
1
Sources per story
7
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering NovoCure Limited. Shared-story counts are live from our verified record — not editorial picks.
NovoCure and Supernus Pharmaceuticals reported Q4 2025 results, highlighting a pivotal year for commercial expansion in oncology and CNS markets. Both companies are navigating the transition from R&D-heavy phases to sustained commercial growth following key regulatory milestones.
NovoCure Limited is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.